PLX Protalix BioTherapeutics Inc

Price (delayed)

$1.09

Market cap

$51.3M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.53

Enterprise value

$67.81M

Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx®. Protalix was the first company to ...

Highlights
PLX's debt is down by 45% YoY
PLX's net income has dropped by 79% year-on-year but it is up by 12% since the previous quarter
PLX's EPS is down by 39% year-on-year but it is up by 15% since the previous quarter
Protalix BioTherapeutics's equity has shrunk by 152% YoY and by 24% QoQ

Key stats

What are the main financial stats of PLX
Market
Shares outstanding
47.06M
Market cap
$51.3M
Enterprise value
$67.81M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
1.16
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.57
Earnings
Revenue
$43.12M
EBIT
-$18.68M
EBITDA
-$17.58M
Free cash flow
-$7.58M
Per share
EPS
-$0.53
Free cash flow per share
-$0.17
Book value per share
-$0.16
Revenue per share
$0.94
TBVPS
$1.49
Balance sheet
Total assets
$68.39M
Total liabilities
$75.88M
Debt
$33.4M
Equity
-$7.49M
Working capital
$21.21M
Liquidity
Debt to equity
-4.46
Current ratio
1.6
Quick ratio
1.1
Net debt/EBITDA
-0.94
Margins
EBITDA margin
-40.8%
Gross margin
59.1%
Net margin
-56.6%
Operating margin
-43.2%
Efficiency
Return on assets
-29.2%
Return on equity
N/A
Return on invested capital
-39%
Return on capital employed
-56.5%
Return on sales
-43.3%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

PLX stock price

How has the Protalix BioTherapeutics stock price performed over time
Intraday
-0.91%
1 week
0%
1 month
2.83%
1 year
-44.1%
YTD
31.06%
QTD
2.83%

Financial performance

How have Protalix BioTherapeutics's revenue and profit performed over time
Revenue
$43.12M
Gross profit
$25.5M
Operating income
-$18.63M
Net income
-$24.39M
Gross margin
59.1%
Net margin
-56.6%
PLX's net margin has plunged by 118% YoY but it is up by 21% from the previous quarter
PLX's net income has dropped by 79% year-on-year but it is up by 12% since the previous quarter
The gross profit has declined by 37% year-on-year but it is up by 16% since the previous quarter
Protalix BioTherapeutics's gross margin has decreased by 23% YoY but it has increased by 3% QoQ

Growth

What is Protalix BioTherapeutics's growth rate over time

Valuation

What is Protalix BioTherapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
1.16
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.57
PLX's EPS is down by 39% year-on-year but it is up by 15% since the previous quarter
Protalix BioTherapeutics's equity has shrunk by 152% YoY and by 24% QoQ
PLX's price to sales (P/S) is 50% lower than its 5-year quarterly average of 2.3 and 11% lower than its last 4 quarters average of 1.3
Protalix BioTherapeutics's revenue has decreased by 18% YoY but it has increased by 12% from the previous quarter

Efficiency

How efficient is Protalix BioTherapeutics business performance
The ROA has plunged by 68% YoY but it has grown by 2.7% from the previous quarter
PLX's return on sales is up by 19% since the previous quarter
The return on invested capital has increased by 2.3% since the previous quarter

Dividends

What is PLX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for PLX.

Financial health

How did Protalix BioTherapeutics financials performed over time
PLX's total assets is 10% smaller than its total liabilities
The company's current ratio rose by 43% YoY but it fell by 14% QoQ
PLX's total assets is down by 33% year-on-year and by 7% since the previous quarter
Protalix BioTherapeutics's equity has shrunk by 152% YoY and by 24% QoQ
PLX's debt is down by 45% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.